Alexander Bozanich, MD
Pulmonary Disease · Munster, INNPI 1255302576
Payments from drug & device makers
Across 314 payments — averaging $24.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Veran Medical Technologies, Inc.$1K
- GSK$827
- AstraZeneca$772
- Harmony Biosciences LLC$550
- Mallinckrodt Hospital Products Inc.$542
- Jazz Pharmaceuticals Inc.$519
- plus $3K from 27 others
What the payments were for
- Travel & lodging$1,12515%
- Food & beverage$6,34584%
- Education$981%
- Entertainment$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Veran Medical Technologies, Inc. | 7 | $1,322 |
| GSK | 71 | $827 |
| AstraZeneca | 44 | $772 |
| Harmony Biosciences LLC | 18 | $550 |
| Mallinckrodt Hospital Products Inc. | 23 | $542 |
| Jazz Pharmaceuticals Inc. | 22 | $519 |
| Johnson & Johnson(2 entities) | 8 | $513 |
| Actelion Pharmaceuticals US, Inc. | 14 | $292 |
| Boehringer Ingelheim | 19 | $292 |
| Idorsia Pharmaceuticals US Inc | 8 | $210 |
| Mylan Specialty L.p. | 12 | $200 |
| Avadel CNS Pharmaceuticals, LLC | 6 | $195 |
| Baxter Healthcare | 7 | $192 |
| Sanofi | 8 | $153 |
| ANI Pharmaceuticals, Inc. | 6 | $132 |
| Inspire Medical Systems, Inc. | 1 | $98 |
| Sunovion Pharmaceuticals Inc. | 6 | $96 |
| Vanda Pharmaceuticals Inc. | 3 | $87 |
| Amgen | 4 | $83 |
| Regeneron Healthcare Solutions, Inc. | 3 | $68 |
| Advanced Respiratory, Inc | 3 | $68 |
| Bayer | 4 | $60 |
| Axsome Therapeutics, Inc. | 3 | $53 |
| Grifols USA, LLC | 3 | $51 |
| Mallinckrodt Enterprises LLC | 2 | $40 |
| Genentech USA, Inc. | 2 | $37 |
| United Therapeutics Corporation | 1 | $23 |
| Pulmonx Corporation | 1 | $20 |
| Philips North America LLC | 1 | $20 |
| Insmed, Inc. | 1 | $20 |
| Fisher & Paykel Healthcare Inc | 1 | $17 |
| Circassia Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Spin$1,256
- Monarch Platform$411
- XYWAV$224
How this compares
$7,583 in reported general payments places this provider in the 70th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 12 | $1,055,616 |
| OfevNintedanib Esylate | 24 | $315,628 |
| OpsumitMacitentan | 14 | $176,339 |
| AdempasRiociguat | 12 | $169,347 |
| LetairisAmbrisentan | 11 | $139,742 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 151 | $108,546 |
| WakixPitolisant Hcl | 13 | $103,304 |
| Dupixent PenDupilumab | 24 | $90,150 |
| Breo ElliptaFluticasone/Vilanterol | 99 | $43,167 |
| Spiriva RespimatTiotropium Bromide | 24 | $18,614 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $15,841 |
| Incruse ElliptaUmeclidinium Bromide | 40 | $12,875 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $12,648 |
| SymbicortBudesonide/Formoterol Fumarate | 49 | $12,312 |
| Ambrisentan | 17 | $11,946 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $542 | $1,055,61612 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $292 | $342,52262 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $827 | $179,579321 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $292 | $176,33914 claims |
| BayerAdempas | $60 | $169,34712 claims |
| Harmony Biosciences LLCWakix | $550 | $103,30413 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $772 | $28,15372 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Munster
- Asaad JandaliMunster$161K
- Fadi LayousMunster$64K
- Bassem SrourMunster$16K
- Wassim ShwaikiMunster$16K
- Cynthia BrownIndianapolis$7.3M
- Imad ShawaGreenwood$1.4M
- David MaresAnderson$1.3M
- Raja DevanathanHobart$862K
- Olusegun ApataGary$780K
- David WilsonSeymour$689K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.